1 citations
,
October 2020 in “Current Drug Discovery Technologies” The research found that compound 6, a newly created steroid, is more effective at inhibiting 5α-reductase (an enzyme) than current treatments, suggesting it could be a better option for treating urinary tract symptoms in men.
1 citations
,
July 2024 in “The International Journal of Medical Science and Health Research” 5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.
1 citations
,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other compounds may help treat hair loss by inhibiting 5-alpha reductase.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules from plants may help treat hair loss.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules from plants may help treat hair loss.
May 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Jamogenin and other molecules may help treat hair loss by inhibiting 5-alpha reductase.
January 2024 in “Brazilian Journal of Hair Health” Some plant-based products might treat hair loss with fewer side effects than current medications.
May 2025 in “Frontiers in Bioinformatics” Jamogenin from plants may help hair growth and is a potential alternative to finasteride.
January 2026 in “Open Science Framework” Oral and topical 5-alpha reductase inhibitors affect DHT levels and hair density differently in treating hair loss.
March 2023 in “Translational Andrology and Urology” 5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
March 2010 in “The Journal of Urology” Methylation of the 5-AR2 gene may cause resistance to Finasteride in BPH patients.
March 2026 in “Journal of Clinical Oncology” Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.
February 2026 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
January 2026 in “Figshare” Finasteride can cause melasma, especially in people with darker skin.
November 2025 in “Mendeley Data” Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
August 2025 in “medRxiv (Cold Spring Harbor Laboratory)” 5-alpha reductase inhibitors may increase depression risk by 31%, but results vary based on comparison groups.
March 2025 in “Scientific Reports” Higher doses of 5α-reductase inhibitors may lower mortality risk, but low doses increase it.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
April 2024 in “Expert opinion on emerging drugs” New treatments for male hair loss are being explored to improve effectiveness and reduce side effects.
February 2024 in “The Journal of Sexual Medicine” 5-α reductase inhibitors do not significantly affect male reproductive function but may reduce semen volume.
June 2023 in “Journal of Cosmetic Dermatology” Finasteride 5mg daily is the most effective for female pattern hair loss, with higher doses of treatments generally more effective.
May 2023 in “Acta Oncologica” 5α-reductase inhibitors do not improve survival in oesophageal and gastric cancer patients.
November 2017 in “International journal of family & community medicine” A man's low testosterone and related symptoms improved after he stopped taking hair loss drugs.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.
March 2016 in “The Journal of Urology” The discovery of 5α-reductase deficiency in guevedoces led to the development of important urologic medications.
April 2012 in “The Journal of Urology” Persistent ED in Propecia users is not due to abnormal blood flow.
January 2002 in “Dialnet (Universidad de la Rioja)” Finasteride treatment makes the prostate look more like a healthy one.